Form 8-K - Current report:
SEC Accession No. 0001213900-25-015735
Filing Date
2025-02-20
Accepted
2025-02-20 17:15:08
Documents
16
Period of Report
2025-02-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0231647-8k_lomond.htm   iXBRL 8-K 34924
2 EXCLUSIVE LICENSE AGREEMENT, DATED FEBRUARY 13, 2025, BY AND BETWEEN LOMOND THER ea023164701ex10-1_lomond.htm EX-10.1 163023
3 EXCLUSIVE LICENSE AGREEMENT, DATED FEBRUARY 13, 2025, BY AND BETWEEN LOMOND THER ea023164701ex10-2_lomond.htm EX-10.2 175692
  Complete submission text file 0001213900-25-015735.txt   674427

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cik0001900520-20250213.xsd EX-101.SCH 3344
5 XBRL DEFINITION FILE cik0001900520-20250213_def.xml EX-101.DEF 26675
6 XBRL LABEL FILE cik0001900520-20250213_lab.xml EX-101.LAB 36628
7 XBRL PRESENTATION FILE cik0001900520-20250213_pre.xml EX-101.PRE 25330
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0231647-8k_lomond_htm.xml XML 4963
Mailing Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901
Business Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901 561 464 2841
Lomond Therapeutics Holdings, Inc. (Filer) CIK: 0001900520 (see all company filings)

EIN.: 872959575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-56377 | Film No.: 25647263
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)